Follow
Jordan Tuia
Title
Cited by
Cited by
Year
The promise and pitfalls of using crowdsourcing in research prioritization for back pain: cross-sectional surveys
MA Bartek, AR Truitt, S Widmer-Rodriguez, J Tuia, ZA Bauer, ...
Journal of medical Internet research 19 (10), e341, 2017
172017
Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020
MD Miljković, JE Tuia, T Olivier, A Haslam, V Prasad
JAMA internal medicine 182 (12), 1319-1320, 2022
142022
Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
A Haslam, T Olivier, J Tuia, V Prasad
BMC cancer 23 (1), 46, 2023
62023
Cost of drug wastage from dose modification and discontinuation of oral anticancer drugs
M Lam, T Olivier, A Haslam, J Tuia, V Prasad
JAMA oncology 9 (9), 1238-1244, 2023
52023
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
A Walia, J Tuia, V Prasad
Nature Reviews Clinical Oncology 20 (12), 885-895, 2023
42023
Profile of the oncology physician workforce and the characteristics of attrition
J Tuia, A Haslam, V Prasad
JCO Oncology Practice 19 (7), 465-472, 2023
32023
Eventual success rate and predictors of success for oncology drugs tested in phase I trials
A Haslam, T Olivier, K Powell, J Tuia, V Prasad
International journal of cancer 152 (2), 276-282, 2023
32023
A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target
A Haslam, T Olivier, J Tuia, V Prasad
European Journal of Cancer 178, 227-233, 2023
32023
Systematic review and meta-analysis of randomized trials testing interventions to reduce physician burnout
A Haslam, J Tuia, SL Miller, V Prasad
The American Journal of Medicine, 2023
12023
Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
T Olivier, A Haslam, J Tuia, V Prasad
JAMA Network Open 6 (10), e2338612-e2338612, 2023
12023
Scoping review of published oncology meta-analyses in high-impact oncology journals
A Haslam, J Tuia, V Prasad
JAMA network open 6 (6), e2318877-e2318877, 2023
12023
Frequency and characteristics of trials using medical writer support in high-impact oncology journals
E Buck, A Haslam, J Tuia, V Prasad
JAMA network open 6 (2), e2254405-e2254405, 2023
12023
A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers
V Prasad, A Haslam, J Tuia
Journal of Cancer Policy 31, 100319, 2022
12022
Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis
M Lam, T Olivier, A Haslam, J Tuia, V Prasad
2024
Assessing patient burden and benefit: A decade of cabozantinib clinical trials
GK Hughes, NB Sajjadi, B Gardner, JK Ramoin, J Tuia, A Haslam, ...
International Journal of Cancer 154 (8), 1464-1473, 2024
2024
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review
P Crotty, K Kari, GK Hughes, C Ladd, R McIntire, B Gardner, AM Peña, ...
Targeted Oncology, 1-13, 2024
2024
Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy
S Ranganathan, A Haslam, J Tuia, V Prasad
Journal of Cancer Policy 39, 100462, 2024
2024
Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials
B Dennis, C Bratten, GK Hughes, AM Peña, R McIntire, C Ladd, ...
BMJ Oncology 3 (1), 2024
2024
Cancer Drug Price and Novelty in Mechanism of Action
MD Miljković, J Tuia, T Olivier, A Haslam, V Prasad
JAMA Network Open 6 (12), e2347006-e2347006, 2023
2023
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Enzalutamide Clinical Trials
JK Stadler, W Compton, GK Hughes, A Peña, R McIntire, C Ladd, ...
7th Annual Joint Research Meeting: Biomedical, Biological, Neuroscience …, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20